SCHEMBL1925168

SCHEMBL1925168

FC(F)(F)[N+](c1ccccc1)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
TSHR P16473 3/20 0.43
LMNA P02545 1/20 0.39
KIF11 P52732 1/20 0.36
CES1 P23141 2/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTPN1 P18031 1/20 0.33
MAPT P10636 2/20 0.32
ALOX15 P16050 1/20 0.32
RECQL P46063 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA5A P35218 1/20 0.32
CA9 Q16790 1/20 0.32
KCNN4 O15554 1/20 0.30
TRPV6 Q9H1D0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9637275 0.69 ALDH1A1 (0.33) ALDH1A1TSHRLMNA
SCHEMBL3913823 0.69 ALDH1A1 (0.39) ALDH1A1TSHRLMNACYP3A4HPGD
SCHEMBL3108934 0.67
SCHEMBL451030 0.65 ALDH1A1 (0.47) ALDH1A1TSHRLMNACYP3A4HPGD
SCHEMBL21082645 0.62 TSHR (0.58) ALDH1A1TSHRKIF11CES1PTPN1
SCHEMBL1052826 0.61 ALDH1A1 (0.41) ALDH1A1TSHRKIF11CES1HPGD
SCHEMBL2119823 0.61 ALDH1A1 (0.38) ALDH1A1TSHRLMNACYP3A4HPGD
SCHEMBL30619668 0.61 TSHR (0.55) ALDH1A1TSHRKIF11CES1PTPN1
Trifluoromethylbenzene SCHEMBL175647 0.60 TSHR (1.00) ALDH1A1TSHRKIF11CES1PTPN1
SCHEMBL9644038 0.60 ALDH1A1 (0.43) ALDH1A1TSHRLMNACYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479397-B1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2011-06-08 EP disclosed
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2008-09-18 US disclosed
US-7375222-B2 2,4,6-Triamino-1,3,5-triazine derivative ASTELLAS PHARMA INC. (JP) 2008-05-20 US disclosed
US-20060194803-A1 2,4,6-Triamino-1,3,5-triazine derivative ASTELLAS PHARMA INC. (JP) 2006-08-31 US disclosed
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US disclosed
EP-1479397-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-11-24 EP disclosed
EP-1446110-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES Structural Bioinformatics Inc. (US) 2004-08-18 EP disclosed
WO-2003032916-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES STRUCTURAL BIOINFORMATICS INC. (US) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases PTPRS, PTPRJ, PTPRCAP ALDH1A1 961/4885TSHR 1917/4885LMNA 4884/4885
US-20060194803-A1 2,4,6-Triamino-1,3,5-triazine derivative KCNT1, KCNMA1, KCNJ2 ALDH1A1 2383/4885TSHR 4742/4885LMNA 3239/4885
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE KCNT1, KCNMA1, KCNJ2 ALDH1A1 2383/4885TSHR 4742/4885LMNA 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.